ClinicalTrials.gg
CompletedNCT00623714Updated May 5, 2015Results posted

Induced Sputum Study (0000-065)

A Phase 1 interventional study of Comparator: fluticasone and Placebo in Asthma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-05-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
135th of 146
13 · median 100
Started
2008
with 4 others
Phase 1
22 of 147
none open now
Registered
49th of 147
by date

Among the 147 studies testing fluticasone in Asthma, this one is the 135th largest by enrollment of the 146 interventional ones that give a count, is one of 5 that started in 2008, is one of 22 in phase 1, and was the 49th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The primary goals of this study will be to implement innovative processing and detection assays to qualify induced sputum measurements of markers of allergen-induced airway inflammation. The results of this study are intended to form a platform to be used in the clinical development of novel asthma therapeutics.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has a history of mild to moderate persistent allergic asthma for at least 6 months with typical symptoms, including cough, wheezing, and shortness of breath, is clinically stable and has no history of recent respiratory tract infection within 3 weeks of the start of the study
  • Patient, aside history of asthma, is judged to be in good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests.
  • Patient is able to perform reproducible pulmonary function test.
  • Patient has an allergic response to house dust mite allergen, demonstrates a positive early and late phase response to an inhaled allergen challenge (as defined by a bronchoconstrictive response)
  • Patient is a nonsmoker for at least 12 months. Patients must have less than or equal to 10 pack years of smoking to be included. (10 pack years = one pack per day for 10 years.) Patients who have discontinued smoking for at least 10 months may be enrolled at the discretion of the investigator
  • Patient is willing to avoid strenuous physical activity (i.e., strenuous or unaccustomed weight lifting, running, bicycling, etc.) for 72 hours prior to each visit when laboratory safety tests are obtained and 48 hours prior to allergen challenge

Exclusion criteria

Exclusion Criteria:

  • Patient has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses additional risk to the patient by their participation in the study
  • Patient has taken oral within 8 weeks or inhaled corticosteroids/nasal corticosteroids within 4 weeks of screening and/or during the study
  • Patient has a history of stroke, chronic seizures, or major neurological disorder
  • Patient has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory (other than asthma), or genitourinary abnormalities or diseases, or has a history of neoplastic disease
  • Patient is unable to refrain from or anticipates the use of any medication other than the ones permitted in this study, including prescription and non-prescription drugs or herbal remedies prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods), until the poststudy visit
  • Patient consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages per day or >21 drink equivalents per week.
  • Patient consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola, or other caffeinated beverages per day
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Arm 1

    study medication + Pbo

    Drug: Comparator: fluticasone · Drug: Placebo

  • Experimental
    Arm 2

    Pbo + study medication

    Drug: Comparator: fluticasone · Drug: Placebo

Interventions

  • Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.

    Also known as: fluticasone

  • DrugPlacebo

    Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.

06

What researchers measure

Primary outcomes

  1. Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL)

    Time frame: Baseline and 24 hours post allergen challenge

Secondary outcomes

  1. Hour 24 Fold Change From Period Baseline in Interleukin-13 (IL-13) Protein Concentration (pg/mL)

    Time frame: Baseline and 24 hours post allergen challenge

07

Results

Posted Jun 22, 2010

Participant flow

First Patient Entered: 28-Jan-2008 Last Patient, Last Visit: 05-Mar-2009 1 site

Period 1
Participant flow — Period 1
MilestonePlacebo Then FluticasoneFluticasone Then Placebo
Started67
Completed67
Not completed00
Period 2
Participant flow — Period 2
MilestonePlacebo Then FluticasoneFluticasone Then Placebo
Started67
Completed67
Not completed00

Outcome measures

PrimaryHour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL)
Time frame:
Baseline and 24 hours post allergen challenge
Reported as:
Geometric mean · pg/mL
Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL)
pg/mLPlaceboFluticasone
Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL)2.57 (1.37 to 4.84)0.87 (0.46 to 1.64)
Statistical analysis
  • Placebo vs Fluticasone · ANOVA · p = 0.011 (1-sided, alpha = 0.05) · Geometric mean fold difference: 0.34 · 90% CI 0.16 to 0.70Analysis performed on log-transformed fold change from baseline and results were back-transformed for reporting.
SecondaryHour 24 Fold Change From Period Baseline in Interleukin-13 (IL-13) Protein Concentration (pg/mL)
Time frame:
Baseline and 24 hours post allergen challenge
Reported as:
Geometric mean · pg/mL
Hour 24 Fold Change From Period Baseline in Interleukin-13 (IL-13) Protein Concentration (pg/mL)
pg/mLPlaceboFluticasone
Hour 24 Fold Change From Period Baseline in Interleukin-13 (IL-13) Protein Concentration (pg/mL)2.11 (1.41 to 3.17)0.85 (0.57 to 1.28)
Statistical analysis
  • Placebo vs Fluticasone · ANOVA · p = 0.002 (1-sided, alpha = 0.05) · Geometric mean fold difference: 0.40 · 95% CI 0.26 to 0.63Analysis performed on log-transformed fold change from baseline and results were back-transformed for reporting.

Adverse events

Collected over Adverse experiences were collected from the time the consent is signed through the 14 day follow up period after all treatment periods were completed. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/13 (0%)5/13 (38.5%)
Fluticasone—0/13 (0%)6/13 (46.2%)
Most frequent other events
Most frequent other events
EventPlaceboFluticasone
FatigueGeneral disorders1/132/13
HeadacheNervous system disorders2/132/13
NasopharyngitisInfections and infestations1/130/13
RhinitisInfections and infestations1/130/13
Urinary Tract InfectionInfections and infestations1/130/13
Muscle Contractions InvoluntaryNervous system disorders1/131/13
AsthmaRespiratory, thoracic and mediastinal disorders0/131/13
CoughRespiratory, thoracic and mediastinal disorders0/131/13
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders0/131/13
Rhinitis AllergicRespiratory, thoracic and mediastinal disorders0/131/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Patients
Mean25.9 (21 to 43)
Sex: Female, Male
Sex: Female, Male(Participants)All Patients
Female9
Male4
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2008
First posted
Feb 26, 2008
Start
Jan 2008
Primary completionActual
Feb 2009
CompletionActual
Mar 2009
Results first posted
Jun 22, 2010
Last update
May 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00623714
Responsible party
Sponsor
First posted
Feb 26, 2008
Start date
Jan 2008
Primary completion
Feb 2009
Completion
Mar 2009
Results posted
Jun 22, 2010
Last update
May 5, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion